Compare CRNC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | LRMR |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.2M | 332.1M |
| IPO Year | N/A | N/A |
| Metric | CRNC | LRMR |
|---|---|---|
| Price | $12.78 | $3.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $11.50 | ★ $16.71 |
| AVG Volume (30 Days) | ★ 2.0M | 1.5M |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | N/A |
| Revenue This Year | $27.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.94 | $1.61 |
| 52 Week High | $27.50 | $6.91 |
| Indicator | CRNC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 51.60 |
| Support Level | $9.56 | $3.12 |
| Resistance Level | $11.08 | $3.69 |
| Average True Range (ATR) | 0.78 | 0.27 |
| MACD | 0.45 | 0.04 |
| Stochastic Oscillator | 92.64 | 84.56 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.